Metabolic reprogramming in cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
Metabolic reprogramming is a hallmark of cancer and allows tumor cells to meet the increased energy demands required for rapid proliferation, invasion, and metastasis. Indeed, many tumor cells acquire distinctive metabolic and bioenergetic features to survive under conditions of limited resources, mainly using alternative nutrients. Several recent studies have explored the metabolic plasticity of cancer cells with the aim to identify new druggable targets, and therapeutic strategies aimed to limit the access to nutrients have been successfully applied to the treatment of some tumors. Cholangiocarcinoma (CCA), a highly heterogeneous tumor, is the second most common form of primary liver cancer. It is characterized by resistance to chemotherapy and poor prognosis, with 5-year survival lower than 20%. Deregulation of metabolic pathways has been described during the onset and progression of CCA. Increased aerobic glycolysis and glutamine anaplerosis provide CCA cells with the ability to generate biosynthetic intermediates. Other metabolic alterations involving carbohydrates, amino acids and lipids have been shown to sustain cancer cell growth and dissemination. In this review, we discuss the complex metabolic rewiring taking place during CCA development, leading to unique nutrient addiction. The possible role of therapeutic interventions based on metabolic changes is also thoroughly discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Metabolic regulation of gene expression by histone lactylation
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1678-1 · Cited by 4,371
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Self-citationUnderstanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
NRF2, a Transcription Factor for Stress Response and Beyond
He, F., Ru, X., & Wen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134777 · Cited by 1,820
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138
Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V., Borad, M. J., Bridgewater, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,116
Role of amino acid transport and countertransport in nutrition and metabolism.
Christensen, H. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.1.43 · Cited by 1,099
Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.010 · Cited by 1,097
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
The Roles of Autophagy in Cancer
Yun, C. W., & Lee, S. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113466 · Cited by 965 · cited 1×
“Some tumor cells rely on autophagic processes to obtain an adequate amount of amino acids for energy and biosynthesis [15] .”
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921 · cited 1×
“Cholesterol metabolism is also dysregulated in cancer [82].”
Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression
Li, Z., & Zhang, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2070-4 · Cited by 830 · cited 2×
“Tumor cells have an increased demand for amino acids to support their remarkably fast proliferation [97].”
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Sciacovelli, M., Gonçalves, E., Johnson, T. I., Zecchini, V. R., da Costa, A. S. H., Gaude, E., Drubbel, A. V., Theobald, S. J., Abbo, S. R., Tran, M. G. B., et al. (2016) · Nature · doi:10.1038/nature19353 · Cited by 584
Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 555
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Zhu, A. X., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3836 · Cited by 509
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer
Akella, N. M., Ciraku, L., & Reginato, M. J. (2019) · BMC Biology · doi:10.1186/s12915-019-0671-3 · Cited by 373
Avila, M. A., Berasain, C., Torres, L., Martín-Duce, A., Corrales, F. J., Yang, H., Prieto, J., Lu, S. C., Caballería, J., Rodés, J., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80122-1 · Cited by 339
Igal, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq131 · Cited by 321
High-Mannose Glycans are Elevated during Breast Cancer Progression
de Leoz, M. L. A., Young, L. J. T., An, H. J., Kronewitter, S. R., Kim, J., Miyamoto, S., Borowsky, A. D., Chew, H. K., & Lebrilla, C. B. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002717 · Cited by 320
Conjugated Bile Acids Activate the Sphingosine–1–Phosphate Receptor 2 in Primary Rodent Hepatocytes
Studer, E., Zhou, X., Zhao, R., Wang, Y., Takabe, K., Nagahashi, M., Pandak, W. M., Dent, P., Spiegel, S., Shi, R., et al. (2012) · Hepatology · doi:10.1002/hep.24681 · Cited by 320
Molecular Pathogenesis of Cholangiocarcinoma
Labib, P. L., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 310 · cited 1×
“In the liver, elevated levels of bile acids (BA), derived from cholesterol, may cause abnormal cell proliferation and development of CCA [83].”
Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 271
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 264 · cited 1×
“The metabolic status of cancer is also extrinsically influenced by microenvironmental cues, including the availability and composition of nutrients, different oxygen concentrations, acidity, and interaction with the extracellular matrix [18].”
Self-citationIsocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 244
Metabolic rearrangements in primary liver cancers: cause and consequences
Satriano, L., Lewinska, M., Rodrigues, P. M., Banales, J. M., & Andersen, J. B. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0217-8 · Cited by 243
Comito, G., Iscaro, A., Bacci, M., Morandi, A., Ippolito, L., Parri, M., Montagnani, I., Raspollini, M. R., Serni, S., Simeoni, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0688-7 · Cited by 241
Regulation of Bile Acid and Cholesterol Metabolism by PPARs
Li, T., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/501739 · Cited by 241 · cited 1×
“PPARα agonists, used for the metabolic syndrome and obesity, are associated with increased synthesis of cholesterol and bile acid, liver damage, cholangiocyte proliferation and hepatic carcinogenesis [85, 86].”
Alistar, A., Morris, B. B., Desnoyer, R., Klepin, H. D., Hosseinzadeh, K., Clark, C., Cameron, A., Leyendecker, J., D'Agostino, R., Topaloglu, U., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30314-5 · Cited by 233
Serine, glycine and one‑carbon metabolism in cancer (Review)
Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C., Patel, M., Roshal, M., Do, R. K., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 223
Cancer Cells Don’t Live Alone: Metabolic Communication within Tumor Microenvironments
Li, F., & Simon, M. C. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.018 · Cited by 221 · cited 1×
“predominantly in the primary tumor microenvironment [71].”
Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis
Ohshima, K., & Morii, E. (2021) · Metabolites · doi:10.3390/metabo11010028 · Cited by 220
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 210
Holden, P., & Tugwood, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0220001 · Cited by 201 · cited 1×
“PPARα agonists, used for the metabolic syndrome and obesity, are associated with increased synthesis of cholesterol and bile acid, liver damage, cholangiocyte proliferation and hepatic carcinogenesis [85, 86].”
Konteatis, Z., Artin, E., Nicolay, B., Straley, K., Padyana, A. K., Jin, L., Chen, Y., Narayaraswamy, R., Tong, S., Wang, F., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00509 · Cited by 199
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184 · cited 1×
“Moreover, reduction in extracellular glutamine concentration increases cell susceptibility to apoptosis [99].”
Stuart, S. D., Schauble, A., Gupta, S., Kennedy, A. D., Keppler, B. R., Bingham, P. M., & Zachar, Z. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-4 · Cited by 183
Liu, R., Zhao, R., Zhou, X., Liang, X., Campbell, D. J. W., Zhang, X., Zhang, L., Shi, R., Wang, G., Pandak, W. M., et al. (2014) · Hepatology · doi:10.1002/hep.27085 · Cited by 183
Banales, J. M., Iñarrairaegui, M., Arbelaiz, A., Milkiewicz, P., Muntané, J., Muñoz‐Bellvis, L., La Casta, A., Gonzalez, L. M., Arretxe, E., Alonso, C., et al. (2019) · Hepatology · doi:10.1002/hep.30319 · Cited by 179
Lin, Y., Cai, Q., Chen, Y., Shi, T., Liu, W., Mao, L., Deng, B., Ying, Z., Gao, Y., Luo, H., et al. (2022) · Hepatology · doi:10.1002/hep.32099 · Cited by 177
Raggi, C., Correnti, M., Sica, A., Andersen, J. B., Cardinale, V., Alvaro, D., Chiorino, G., Forti, E., Glaser, S., Alpini, G., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.012 · Cited by 172
Self-citationMitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Raggi, C., Taddei, M. L., Sacco, E., Navari, N., Correnti, M., Piombanti, B., Pastore, M., Campani, C., Pranzini, E., Iorio, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.031 · Cited by 168
Self-citationBritten, C. D., Garrett-Mayer, E., Chin, S. H., Shirai, K., Ogretmen, B., Bentz, T. A., Brisendine, A., Anderton, K., Cusack, S. L., Maines, L. W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2363 · Cited by 167
Massard, C., Azaro, A., Soria, J., Lassen, U., Tourneau, C. L., Sarker, D., Smith, C. L., Ohnmacht, U., Oakley, G. J., Patel, B. K. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy244 · Cited by 162 · cited 1×
“This drug has previously been shown to be well tolerated when administered alone, and some clinical activity was reported in a group of patients including CCA [139].”
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
Zhang, S., Song, X., Cao, D., Xu, Z., Fan, B., Che, L., Hu, J., Chen, B., Dong, M., Pilo, M. G., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.006 · Cited by 159
Chaiteerakij, R., Yang, J. D., Harmsen, W. S., Slettedahl, S. W., Mettler, T. A., Fredericksen, Z. S., Kim, R. W., Gores, G. J., Roberts, R. O., Olson, J. E., et al. (2013) · Hepatology · doi:10.1002/hep.26092 · Cited by 149
Sphingosine 1-phosphate signalling in cancer
Pyne, N. J., Tonelli, F., Lim, K. G., Long, J. S., Edwards, J., & Pyne, S. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110602 · Cited by 142
Liu, H., Dong, H., Robertson, K. D., & Liu, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.023 · Cited by 140
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
Gao, L., Xu, Z., Huang, Z., Tang, Y., Yang, D., Huang, J., He, L., Liu, M., Chen, Z., & Teng, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01579-x · Cited by 138
Phoomak, C., Vaeteewoottacharn, K., Silsirivanit, A., Saengboonmee, C., Seubwai, W., Sawanyawisuth, K., Wongkham, C., & Wongkham, S. (2017) · Scientific Reports · doi:10.1038/srep43842 · Cited by 128
Lu, X., Paliogiannis, P., Calvisi, D. F., & Chen, X. (2020) · Hepatology · doi:10.1002/hep.31310 · Cited by 127
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 127
Hansel, D. E., Rahman, A., Hidalgo, M. M., Thuluvath, P. J., Lillemoe, K. D., Shulick, R., Ku, J., Park, J., Miyazaki, K., Ashfaq, R., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63645-0 · Cited by 123
The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
Chung, J., Hong, S., Choi, B. Y., Cho, H., Yu, E., & Hewitt, S. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1084 · Cited by 123
Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth
Alpini, G. D., Invernizzi, P., Gaudio, E., Venter, J. K., Kopriva, S. E., Bernuzzi, F., Onori, P., Franchitto, A., Coufal, M., Frampton, G. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2133 · Cited by 120
Pegylated arginine deiminase: a novel anticancer enzyme agent
Feun, L., & Savaraj, N. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.815 · Cited by 118
Cellular and molecular effects of the mTOR inhibitor everolimus
Saran, U., Foti, M., & Dufour, J. (2015) · Clinical Science · doi:10.1042/cs20150149 · Cited by 116
Li, L., Che, L., Tharp, K. M., Park, H., Pilo, M. G., Cao, D., Cigliano, A., Latte, G., Xu, Z., Ribback, S., et al. (2016) · Hepatology · doi:10.1002/hep.28508 · Cited by 105
Guan, L., Zhang, L., Gong, Z., Hou, X., Xu, Y., Feng, X., Wang, H., & You, H. (2016) · Hepatology · doi:10.1002/hep.28496 · Cited by 101
Murakami, Y., Kubo, S., Tamori, A., Itami, S., Kawamura, E., Iwaisako, K., Ikeda, K., Kawada, N., Ochiya, T., & Taguchi, Y. (2015) · Scientific Reports · doi:10.1038/srep16294 · Cited by 101
Pietrovito, L., Leo, A., Gori, V., Lulli, M., Parri, M., Becherucci, V., Piccini, L., Bambi, F., Taddei, M. L., & Chiarugi, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12189 · Cited by 100
Self-citationEpigenetic reprogramming modulates malignant properties of human liver cancer
Raggi, C., Factor, V. M., Seo, D., Holczbauer, Á., Gillen, M. C., Marquardt, J. U., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2014) · Hepatology · doi:10.1002/hep.27026 · Cited by 96
Self-citationFan, B., Mellinghoff, I. K., Wen, P. Y., Lowery, M. A., Goyal, L., Tap, W. D., Pandya, S. S., Manyak, E. L., Jiang, L., Liu, G., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00771-x · Cited by 94
Qu, X., Sheng, J., Shen, L., Su, J., Xu, Y., Xie, Q., Yao, W., Zhang, X., & Sun, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173712 · Cited by 93
High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation
Saengboonmee, C., Seubwai, W., Pairojkul, C., & Wongkham, S. (2016) · Scientific Reports · doi:10.1038/srep18995 · Cited by 93
Methionine adenosyltransferases in liver cancer
Murray, B., Barbier‐Torres, L., Fan, W., Mato, J. M., & Lu, S. C.-L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4300 · Cited by 93
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 92
Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer
Liu, T., Yang, H., Fan, W., Tu, J., Li, T. W. H., Wang, J., Shen, H., Yang, J., Xiong, T., Steggerda, J. A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.032 · Cited by 91
Molenaar, R. J., Coelen, R. J. S., Khurshed, M., Roos, E., Caan, M. W. A., Linde, M. E. V., Kouwenhoven, M. C. M., Bramer, J. A. M., Bovée, J. V. M. G., Mathôt, R. A. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014961 · Cited by 89
Li, D., Wang, C., Ma, P., Yu, Q., Gu, M., Dong, L., Jiang, W., Pan, S., Xie, C., Han, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0494-0 · Cited by 88
Wang, J., Wang, H., Peters, M., Ding, N., Ribback, S., Utpatel, K., Cigliano, A., Dombrowski, F., Xu, M., Chen, X., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.027 · Cited by 87
Miolo, G., Muraro, E., Caruso, D., Crivellari, D., Ash, A., Scalone, S., Lombardi, D., Rizzolio, F., Giordano, A., & Corona, G. (2016) · Oncotarget · doi:10.18632/oncotarget.9489 · Cited by 87
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Erice, O., Labiano, I., Arbelaiz, A., Santos‐Laso, Á., Muñoz-Garrido, P., Jiménez-Agüero, R., Olaizola, P., Caro‐Maldonado, A., Martín-Martín, N., Carracedo, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.016 · Cited by 86
Improving the Treatment of Acute Lymphoblastic Leukemia
Radadiya, A., Zhu, W., Coricello, A., Alcaro, S., & Richards, N. G. J. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00354 · Cited by 85
Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development
Lozano, E., Sanchez-Vicente, L., Monte, M. J., Herraez, E., Briz, O., Banales, J. M., Marin, J. J. G., & Macias, R. I. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0503 · Cited by 81
Xu, L., Li, Y., Zhou, L., Dorfman, R. G., Liu, L., Cai, R., Jiang, C., Tang, D., Wang, Y., Zou, X., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2089 · Cited by 70
JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma
Manieri, E., Folgueira, C., Rodríguez, M. E., Leiva‐Vega, L., Esteban-Lafuente, L., Chen, C., Cubero, F. J., Barrett, T., Cavanagh, J., Seruggia, D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002672117 · Cited by 70 · cited 1×
“These effects are mediated by PPARα activation [84].”
Thanee, M., Loilome, W., Techasen, A., Sugihara, E., Okazaki, S., Abe, S., Ueda, S., Masuko, T., Namwat, N., Khuntikeo, N., et al. (2016) · Cancer Science · doi:10.1111/cas.12967 · Cited by 70
Buzzoni, R., Pusceddu, S., Bajetta, E., de Braud, F., Platania, M., Iannacone, C., Cantore, M., Mambrini, A., Bertolini, A., Alabiso, O., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu175 · Cited by 69
Expression and roles of fatty acid synthase in hepatocellular carcinoma
Qiwei, H., Li, T., Zhang, X., Gao, P., QIAO, P., Li, S., & Geng, Z. (2014) · Oncology Reports · doi:10.3892/or.2014.3484 · Cited by 65
Fan, W., Yang, H., Liu, T., Wang, J., Li, T. W. H., Mavila, N., Tang, Y., Yang, J., Peng, H., Tu, J., et al. (2016) · Hepatology · doi:10.1002/hep.28964 · Cited by 59
Phoomak, C., Vaeteewoottacharn, K., Sawanyawisuth, K., Seubwai, W., Wongkham, C., Silsirivanit, A., & Wongkham, S. (2016) · Scientific Reports · doi:10.1038/srep27853 · Cited by 58
Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration
Janpipatkul, K., Suksen, K., Borwornpinyo, S., Jearawiriyapaisarn, N., Hongeng, S., Piyachaturawat, P., & Chairoungdua, A. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.002 · Cited by 54
Yang, H., Liu, T., Wang, J., Li, T. W. H., Fan, W., Peng, H., Krishnan, A., Gores, G. J., Mato, J. M., & Lu, S. C.-L. (2016) · Hepatology · doi:10.1002/hep.28541 · Cited by 54
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
de Gauna, M. R., Biancaniello, F., González‐Romero, F., Rodrigues, P. M., Lapitz, A., Gómez‐Santos, B., Olaizola, P., Matteo, S. D., Aurrekoetxea, I., Labiano, I., et al. (2022) · Hepatology · doi:10.1002/hep.32344 · Cited by 54
Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma
Jiang, X., Ma, N., Wang, D., Li, F., He, R., Li, D., Zhao, R., Zhou, Q., Wang, Y., Zhang, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3063 · Cited by 51
Ding, X., Chaiteerakij, R., Moser, C. D., Shaleh, H. M., Boakye, J., Chen, G., Ndzengue, A., Li, Y., Zhou, Y., Huang, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7914 · Cited by 51
Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4
Nie, J., Zhang, J., Wang, L., Lu, L., Qian, Y., An, F., Zhang, S., & Jiao, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0641-y · Cited by 49
Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis.
Thonsri, U., Seubwai, W., Waraasawapati, S., Sawanyawisuth, K., Vaeteewoottacharn, K., Boonmars, T., & Cha’on, U. (2017) · PubMed · doi:10.14670/hh-11-819 · Cited by 46
Lau, D. K., Tay, R. Y., Yeung, Y. H., Chionh, F. J. M., Mooi, J. K., Murone, C., Skrinos, E., Price, T. J., Mariadason, J. M., & Tebbutt, N. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0021-1 · Cited by 46
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 45
O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1
Phoomak, C., Silsirivanit, A., Park, D., Sawanyawisuth, K., Vaeteewoottacharn, K., Wongkham, C., Lam, E. W. ‐., Pairojkul, C., Lebrilla, C. B., & Wongkham, S. (2018) · Oncogene · doi:10.1038/s41388-018-0366-1 · Cited by 45
Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma
Kubo, Y., Aishima, S., Tanaka, Y., Shindo, K., Mizuuchi, Y., Abe, K., Shirabe, K., Maehara, Y., Honda, H., & Oda, Y. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.008 · Cited by 44 · cited 1×
“Expression of the glucose transporter GLUT-1 is correlated to 18 F-FDG uptake, histological differentiation [24] and poor OS [25, 26], supporting the biology behind the clinical relevance of 18 F-FDG PET.”
Yu, Y., Liao, M., Liu, R., Chen, J., Feng, H., & Fu, Z. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-78 · Cited by 43
Dhar, D. K., Damink, S. W. M. O., Brindley, J. H., Godfrey, A. R., Chapman, M. H., Sandanayake, N. S., Andreola, F., Mazurek, S., Hasan, T. G., Malagó, M., et al. (2012) · Cancer · doi:10.1002/cncr.27611 · Cited by 40
Ikeno, Y., Seo, S., Iwaisako, K., Yoh, T., Nakamoto, Y., Fuji, H., Taura, K., Okajima, H., Kaido, T., Sakaguchi, S., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1475-x · Cited by 40
Tomacha, J., Dokduang, H., Padthaisong, S., Namwat, N., Klanrit, P., Phetcharaburanin, J., Wangwiwatsin, A., Khampitak, T., Koonmee, S., Titapun, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696961 · Cited by 39
Delahousse, J., Verlingue, L., Broutin, S., Legoupil, C., Touat, M., Doucet, L. S., Ammari, S., Lacroix, L., Ducreux, M. P., Scoazec, J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.024 · Cited by 39
Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?
Baiocchi, L., Zhou, T., Liangpunsakul, S., Lenci, I., Santopaolo, F., Meng, F., Kennedy, L. L., Glaser, S. S., Francis, H., & Alpini, G. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081869 · Cited by 38
Azaro, A., Massard, C., Tap, W. D., Cassier, P. A., Merchan, J. R., Italiano, A., Anderson, B., Yuen, E., Yu, D., Oakley, G. J., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01094-6 · Cited by 38
Samatiwat, P., Prawan, A., Senggunprai, L., Kukongviriyapan, U., & Kukongviriyapan, V. (2016) · Tumor Biology · doi:10.1007/s13277-016-5015-0 · Cited by 38
Zhang, B., Zhou, B., Xiao, M., Li, H., Guo, L., Wang, M.-X., Yu, S., & Ye, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01025 · Cited by 38
Xu, L., Wang, L., Zhou, L., Dorfman, R. G., Pan, Y., Tang, D., Wang, Y., Yin, Y., Jiang, C., Zou, X., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.002 · Cited by 38
Warburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 37
Matteo, S. D., Nevi, L., Overi, D., Landolina, N., Faccioli, J., Giulitti, F., Napoletano, C., Oddi, A., Marziani, A. M., Costantini, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81172-0 · Cited by 36
Roy, S., Kumaravel, S., Banerjee, P., White, T. K., O’Brien, A., Seelig, C., Chauhan, R., Ekser, B., Bayless, K. J., Alpini, G. D., et al. (2021) · Cells · doi:10.3390/cells10113093 · Cited by 36
Qian, Z., Hu, W., Lv, Z., Liu, H., Chen, D., Wang, Y., Wu, J., & Zheng, S. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.06.008 · Cited by 36
Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy
Kee, H. J., & Cheong, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.273 · Cited by 35 · cited 1×
“Nevertheless, despite promising pre-clinical results, glycolysis inhibitors failed to meet the expectations in the clinic [13].”
Glutamine deprivation counteracts hypoxia-induced chemoresistance
Wappler, J., Arts, M., Röth, A., Heeren, R. M. A., Peter Neumann, U., Olde Damink, S. W., Soons, Z., & Cramer, T. (2020) · Neoplasia · doi:10.1016/j.neo.2019.10.004 · Cited by 34
Padthaisong, S., Phetcharaburanin, J., Klanrit, P., Li, J. V., Namwat, N., Khuntikeo, N., Titapun, A., Jarearnrat, A., Wangwiwatsin, A., Mahalapbutr, P., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00266-5 · Cited by 34
Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 33
Fujiwara, H., Tateishi, K., Misumi, K., Hayashi, A., Igarashi, K., Kato, H., Nakatsuka, T., Suzuki, N., Yamamoto, K., Kudo, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55211-w · Cited by 33
Thanee, M., Padthaisong, S., Suksawat, M., Dokduang, H., Phetcharaburanin, J., Klanrit, P., Titapun, A., Namwat, N., Wangwiwatsin, A., Sa-Ngiamwibool, P., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00249-6 · Cited by 31
UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals
Yu, J., Shi, L., Shen, X., & Zhao, Y. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.05.017 · Cited by 30
Tamai, K., Nakamura, M., Shibuya‐Takahashi, R., Kanno, S., Yasui, A., Mochizuki, M., Iwai, W., Wakui, Y., Abue, M., Yamamoto, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78539-0 · Cited by 30
Pastore, M., Lori, G., Gentilini, A., Taddei, M. L., Maira, G. D., Campani, C., Recalcati, S., Invernizzi, P., Marra, F., & Raggi, C. (2020) · Cells · doi:10.3390/cells9030596 · Cited by 28
Self-citationSaengboonmee, C., Phoomak, C., Supabphol, S., Covington, K. R., Hampton, O. A., Wongkham, C., Gibbs, R. A., Umezawa, K., Seubwai, W., Gingras, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118548 · Cited by 28
Faloppi, L., Prete, M. D., Gardini, A., Santini, D., Silvestris, N., Bianconi, M., Giampieri, R., Valgiusti, M., Brunetti, O., Bittoni, A., et al. (2016) · Scientific Reports · doi:10.1038/srep24136 · Cited by 27
Suzuki, H., Komuta, M., Bolog, A., Yokobori, T., Wada, S., Araki, K., Kubo, N., Watanabe, A., Tsukagoshi, M., & Kuwano, H. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.03.017 · Cited by 26
Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma
Wang, Z., Zheng, T., Wu, Q., WANG, J., Wu, C., & Wang, J. (2011) · Neoplasma · doi:10.4149/neo_2012_018 · Cited by 23
Detarya, M., Thaenkaew, S., Seubwai, W., Indramanee, S., Phoomak, C., Saengboonmee, C., Wongkham, S., & Wongkham, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119114 · Cited by 22
Kim, K., Joo, J., Park, B., Park, S., Lee, W. J., Han, S., Kim, T. H., Hong, E. K., Woo, S. M., & Yoo, B. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22607 · Cited by 20
Zhang, J., Hang, C., Jiang, T., Yi, S., Shao, W., Li, W., & Lin, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.570516 · Cited by 18
Metformin does not improve survival of cholangiocarcinoma patients with diabetes
Yang, Z., Zhang, X., Roberts, R. O., Roberts, L. R., & Chaiteerakij, R. (2015) · Hepatology · doi:10.1002/hep.27821 · Cited by 18 · cited 1×
“In keeping, Yang et al. reported that metformin does not improve survival of CCA in patients with diabetes [70].”
Nakagawa, R., Canh, H. N., Ouchi, H., Sato, Y., & Harada, K. (2019) · Medical Molecular Morphology · doi:10.1007/s00795-019-00230-9 · Cited by 14
Thonsri, U., Wongkham, S., Wongkham, C., Hino, S., Nakao, M., Roytrakul, S., Koga, T., & Seubwai, W. (2020) · Cancer Science · doi:10.1111/cas.14719 · Cited by 14
Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes
Tseng, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587666 · Cited by 14 · cited 1×
“Furthermore, a retrospective study by Tseng et al., demonstrated that metformin significantly decreases the risk of biliary tract cancer by 50%–60%, although does not affect overall survival in these patients [69].”
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice
Ding, N., Che, L., Li, X., Liu, Y., Jiang, L., Fan, B., Tao, J., Chen, X., & Ji, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i6.2071 · Cited by 14
Feichtinger, R. G., Neureiter, D., Kemmerling, R., Mayr, J. A., Kiesslich, T., & Kofler, B. (2019) · Cells · doi:10.3390/cells8060539 · Cited by 14
Cited by
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
“Leveraging genetically engineered mouse models of iCCA, IDH mutations were shown to increase the production of D-2-hydroxyglutarate (D-2-HG), affecting α-ketoglutarate (αKG)-dependent dioxygenases involved in DNA repair and epigenetic remodeling [92].”
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Metadata
- Authors
- Raggi, C., Taddei, M. L., Rae, C., Braconi, C., & Marra, F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 77
- Issue
- 3
- Pages
- 849-864
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4280616882
- Cited by
- 176
- References
- 139
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.